Title:
Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners

Authors:
Carlos Alventosa Mateu, Salvador Benlloch Pérez, Moisés Diago Madrid

DOI: 10.17235/reed.2021.7970/2021
Link: PubMed (Epub ahead of print)

Please cite this article as:

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners

Carlos Alventosa Mateu¹, Salvador Benlloch Pérez², Moisés Diago Madrid¹

¹Department of Digestive Diseases. Consorcio Hospital General Universitario de Valencia (Valencia, Spain). ²Department of Digestive Diseases. Hospital Universitario Arnau de Vilanova (Valencia, Spain). CiberEHD.

Correspondence to: Carlos Alventosa Mateu. Department of Digestive Diseases. Consorcio Hospital General Universitario de Valencia. Av. Tres Cruces Nº 2, PC 46014, Valencia (España). E-mail: almacar84@hotmail.com

Keywords: Coronavirus, SARS-CoV-2, COVID-19, liver damage, hepatitis B reactivation.

Conflict of interest: the authors declare no conflict of interest.

Acknowledgements: to Francesc Puchades Gimeno, Francisco Sanz Herrero and Mercedes Latorre Sánchez.

Dear Editor,

Liver damage, defined by an increase in liver biochemical parameters, is related to a more unfavorable severity and prognosis in patients with COVID-19 (1-3). These patients are also treated with immunomodulatory drugs capable of reactivating the hepatitis B virus (HBV), with indication for prophylaxis in specific situations (4-5). Due to its importance in this pathology, we wondered whether physicians should perform a systematic search for liver damage and HBV.

To this end, we distributed a self-developed survey that evaluated this search in different clinical scenarios and asked for respondents' opinions on the association between liver damage and severity and prognosis in patients with COVID-19. 173 responses were obtained from 13 hospitals. The respondents' medical specialties and
usual places of work with COVID-19 patients were varied. A total of 54.9% of respondents carried out a systematic search for liver damage, mainly because it is protocol at their place of work. Less than 45% of respondents carried out daily or sporadic searches for liver damage among hospitalized patients, including in patients with known liver disease, and less than 25% carried out a closer clinical / analytical follow-up when it presented. Only 41% performed outpatient lab monitoring in patients with liver damage upon discharge. A systematic search for HBV was performed by 36.4% of respondents, and 19.7% of them only ordered it if immunomodulating treatment was going to be initiated. Finally, 64.7% of respondents considered that there was no relevant association between liver disease and unfavorable severity/prognosis, while only 9.8% considered the association to be relevant (Fig. 1). This last percentage was just as low in the sub-analysis by medical specialty, except for Anesthesiology / Intensive Care, which was 26%.

In conclusion, respondents’ search for liver damage and HBV is sub-optimal. We believe that strategies are required to raise awareness of its clinical and prognostic importance.

REFERENCES

1. What has been your engagement with COVID-19 patients in recent months? Exclusive (28.9%); Partial (36.6%); Sporadic (14.5%).

2. Where do you primarily care for these patients? Hospitalization ward (61.3%); Emergency Room (11%); Intensive care unit (17.9%); Primary care (5.2%); Other (4.8%).

3. What is your medical specialty? Internal Medicine/Infectious diseases (27.7%); Pneumology (8.6%); Anesthesiology/Intensive care (19.7%); Family Medicine (11.6%); Digestive diseases (21.4%); Other (11%).

4. What is your professional experience? Residency (17.9%); Specialised Doctor since less than 10 years (46.2%); Specialised Doctor since more than 10 years (35.8%).

5. Do you test for total bilirubin, AST, ALT, alkaline phosphate and GGT in the initial assessment of the COVID-19 patient? Always (54.9%); Only if hospitalization is required (36.4%); Only if patient presents with known liver disease (6.4%); No (5.4%); DK/NR (2.3%).

6. What is the main reason for performing these tests? It is protocol at my site (72.3%); I am performing an active search (23.1%); I think they are of prognostic importance (27.7%); There is no specific reason (4%); DK/NR (4.6%).

7. If these tests are normal for diagnosis of COVID-19 in hospitalized patients WITHOUT known liver disease, do you carry out additional tests during their hospital follow-up? Daily (21.4%); Sporadically (43.9%); Only if clinical outcome is unfavorable (13.3%); No (5.8%); DK/NR (15.6%).

8. If these tests are normal for diagnosis of COVID-19 in hospitalized patients WITH known liver disease, do you carry out additional tests during their hospital follow-up? Daily (36.4%); Sporadically (38.2%); Only if clinical outcome is unfavorable (5.8%); No (3.4%); DK/NR (16.2%).

9. If you are dealing with an asymptomatic or mild case and find it necessary to order a blood analysis, do you include these tests? Always (50.9%); Only if patient presents with known liver disease (20.4%); Only on certain occasions (26.2%); Never (6.9%); DK/NR (15%).

10. Do you request viral hepatitis B serology in patients with COVID-19? Always (16.4%); Only if they present with abnormal liver function parameters (12.1%); Only if I am going to prescribe immunomodulating treatment for COVID-19 (19.7%); No (25.4%); DK/NR (6.4%).

11. If patients are discharged with liver damage, do you perform subsequent liver biochemistry checks? Always (31.2%); Only if patient presents with known liver disease (5.8%); Only if patient was severely ill or experienced a drastic change in condition (12.7%); No (9.2%); DK/NR (41.1%).

12. If liver damage is confirmed, do you change patient handling or follow-up? No (3.5%); I do not change treatment, but I follow up with more precise clinical/analytical work (22.5%); I do not change treatment, but I request additional examinations and drug hepatotoxicity (46.8%); Yes, change or intensify treatment (13.3%); DK/NR (13.9%).

13. What do you think about the association between liver damage and the severity/prognosis of COVID-19 patients? There is a relevant association with unfavorable severity/progression (9.8%); There is a non-relevant association with unfavorable severity/progression (64.7%); There is a non-relevant association with favorable severity/progression (1.2%); There is no association (9.8%); DK/NA (14.5%).

Figure 1: List of questions and possible survey responses. Percentages are indicated in brackets after each answer, with the highest percentage in bold. Question 6 was the
only one with multiple answers. DK/NR: Doesn't know/No response.